In recent years, urologists and patient advocates have promoted proposals to require insurers to cover prostate cancer screening without copay, coinsurance, or cost sharing. These efforts have borne fruit in Maryland and New York, where state laws now place prostate cancer screening on par with breast cancer screening when it comes to cost-free coverage.
It should come as no surprise that health insurance companies are fierce opponents of these campaigns. Chambers of commerce, too, vigorously oppose the benefit mandates that, in the short term, increase insurance premiums. What’s astounding, however, is that most state governments themselves tip the scales toward the defeat of new patient-centered coverage requirements in the form of “mandated benefit review” laws.